%A 于兰，张小涛，李进英，王玉 %T Clinical application of FOLFIRINOX regimen for pancreatic cancer %0 Journal Article %D 2017 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2017.11.018 %P 874-878 %V 44 %N 11 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10356.shtml} %8 2017-11-08 %X Clinical studies have confirmed the FOLFIRINOX regimen (oxaliplatin+irinotecan+fluorouracil+leucovorin) is an effective regimen for advanced pancreatic cancer patients with good performance status. Current clinical studies on FOLFIRINOX regimen mainly include neoadjuvant therapy for unresectable and borderline resectable pancreatic cancer and firstline therapy for locally advanced pancreatic cancer and metastatic pancreatic cancer, which improved patient′s surgical resection opportunities and survival. In addition, the toxicity, safety of FOLFIRINOX regimen and effective population selection for FOLFIRINOX regimen are also the problems concerned by researchers.